Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814069 | 0.79 | — | — | |
| SCHEMBL14342918 | 0.78 | PDE4B (0.32) | PDE4B | |
| Hydrochloric Acid SCHEMBL5313449 | 0.76 | PDE4B (0.31) | PDE4B | |
| SCHEMBL7677629 | 0.73 | CHRNB2 (0.31) | PDE4B | |
| SCHEMBL15011974 | 0.72 | PDE4B (0.33) | PDE4B | |
| Hydrochloric Acid SCHEMBL15121983 | 0.71 | PDE4B (0.32) | PDE4B | |
| Hydrochloric Acid SCHEMBL15012036 | 0.71 | — | — | |
| SCHEMBL5160130 | 0.68 | RAB9A (0.37) | PDE4B | |
| SCHEMBL10242473 | 0.68 | — | — | |
| SCHEMBL20331851 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7329755-B2 | especially naphthalene sulfonamides, used for treating asthma | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1590327-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1581511-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040224978-A1 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| US-20040209948-A1 | CCR8 Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004058709-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058736-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | PDE4B 1760/4885MMP1 453/4885MMP3 359/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | PDE4B 1483/4885MMP1 335/4885MMP3 359/4885 |
| US-20040209948-A1 | CCR8 Inhibitors | CCR8, CCR1, CCR3 | PDE4B 737/4885MMP1 239/4885MMP3 537/4885 |
| US-20040224978-A1 | CCR8 inhibitors | CCR8, CCR1, CCRL2 | PDE4B 2174/4885MMP1 198/4885MMP3 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.